Re: A clinical future for RVX-2135 or just a pre-clinical tool
in response to
by
posted on
Aug 17, 2017 02:37PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Toinv - Thanks for the commentary. I'm glad you had success. This board would be lacking without your commentary. My scientific knowledge is limited so anyone who sees an error in my comments below please feel free to correct me.
The genome was mapped somewhere around the year 2000, right around the height of the tech bubble. From that point the development of designer drugs exploded as it became easier for the medical community to determine which drugs would work best or better for patients because of their genetic makeup. Prior to that point it was more of a random process. The further out we go the more science is available to assist in the determination of what drugs would works best for what patients. Now we, ZEN and RVX are dealing with an epigenetic situation, one level above the gene level.
The scientists developing drugs today have many more tools available to them than even 10 or 20 years ago. It would be surprising to me if the doctors running trials today didn't have a pretty good idea in the recruiting stages of many trials, whether the drug they are testing should work better on one particular recruit versus another. For example RVX-208 worked best on patients that were diabetic or pre diabetic with low HDL and high CRP. I don't know but have an idea that the doctors running this current Zenith trial will have screened the patients to use the ones that have the best chance of success based on their genetic or epigenetic makeup.
As for our (ZEN and RVX) situation, we seem to be leading the field by 7/8 years. This is both good and bad as we are the ones that everyone else will compare to. If our scientists are correct, which will be more or less proven over the next 2 years or less then the value of these companies could end up being something that people will be talking about for quite some time. Our hope as shareholders is that the science is correct and what people talk about is the riches we came into by taking the risks that we are today. For the patients having 6 months or two years of additional life or maybe even a cure for their ailment would be awesome.
tada
dyodd